vilobelimab + paridiprubart + bevacizumab

This is a **combination therapy** consisting of three monoclonal antibodies: - **Vilobelimab**: a chimeric IgG4 monoclonal antibody that binds to and neutralizes complement factor 5a (C5a), inhibiting its inflammatory effects. It is approved under exceptional circumstances in the EU for SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) in adults and received emergency use authorization in the US for COVID-19 in patients requiring mechanical ventilation. Vilobelimab reduces C5a-induced inflammation, thus attenuating tissue damage[2][3][4][8]. - **Paridiprubart**: a monoclonal antibody targeting complement factor C5a. Publicly available data for paridiprubart are limited. Its mechanism and modality are presumed to be similar to vilobelimab, targeting complement pathway activation. - **Bevacizumab**: a humanized monoclonal antibody that binds vascular endothelial growth factor A (VEGF-A), preventing interaction with its receptors (VEGFR1/Flt-1 and VEGFR2/KDR) on endothelial cells, thus inhibiting angiogenesis. Bevacizumab is indicated for several solid tumors and is under investigation for COVID-19 complications including ARDS[1][5][6]. Together, the combination targets both **complement-mediated inflammation** and **VEGF-driven angiogenesis**, making it a potential therapeutic strategy for severe inflammatory conditions such as **ARDS**, severe COVID-19, and possibly other diseases where both immune and vascular pathways are dysregulated.

Other names

anti-C5a antibodyanti-C-5a antibodyanti-C 5a antibodycomplement factor 5a monoclonal antibodyanti-VEGF monoclonal antibody